AS INTERAÇÕES MEDICAMENTOSAS NA TERAPIA DE REPOSIÇÃO HORMONAL EM PACIENTES COM CÂNCER DE MAMA: UMA REVISÃO SISTEMÁTICA

Maria Carolina Marques de Sousa  Araújo; Ana Claudia Costa Guilhen; Andre de Figueredo Maciel; Brenda  Portes; Natalia  Sales Corazza Luciano; Andrey Borges Teixeira

doi:10.69719/ros.v8.872

Autores

Maria Carolina Marques de Sousa Araújo Centro Universitário de Adamantina - FAI https://orcid.org/0000-0002-5753-0526
Ana Claudia Costa Guilhen Centro Universitário de Adamantina - FAI https://orcid.org/0009-0000-8072-8656
Andre de Figueredo Maciel Centro Universitário de Adamantina - FAI https://orcid.org/0009-0002-6610-3662
Brenda Portes Centro Universitário de Adamantina https://orcid.org/0009-0009-9321-2873
Natalia Sales Corazza Luciano Centro Universitário de Adamantina - FAI https://orcid.org/0009-0005-9809-2357
Andrey Borges Teixeira Centro Universitário de Adamantina - FAI https://orcid.org/0009-0005-7575-4434

DOI:

https://doi.org/10.69719/ros.v8.872

Palavras-chave:

terapia de reposição hormonal, câncer de mama, interações medicamentosas, tamoxifeno, farmacocinética

Resumo

A terapia de reposição hormonal (TRH) é amplamente utilizada para atenuar os sintomas do climatério, porém sua segurança em pacientes com histórico de câncer de mama permanece controversa, sobretudo devido ao risco de interações medicamentosas com fármacos antineoplásicos. Este estudo teve como objetivo realizar uma revisão sistemática da literatura para identificar, classificar e analisar as principais interações medicamentosas entre agentes utilizados na TRH e tratamentos empregados em pacientes com câncer de mama. A busca foi conduzida nas bases de dados PubMed, SciELO e LILACS, utilizando os descritores “Hormone Replacement Therapy”, “Breast Cancer” e “Drug Interactions”, combinados com os operadores booleanos AND e OR. Foram incluídos 50 estudos publicados entre 2002 e 2024, com base em critérios de elegibilidade pré-definidos. Os resultados demonstraram que o uso concomitante de TRH com fármacos como tamoxifeno, inibidores da aromatase e antidepressivos ISRS pode gerar interações farmacocinéticas e farmacodinâmicas relevantes, especialmente por modulação enzimática via citocromo P450. A via de administração, o tipo hormonal e o tempo de exposição também influenciam diretamente no risco oncológico. Conclui- se que o uso da TRH em pacientes com câncer de mama deve ser considerado apenas em situações específicas, com avaliação individualizada e acompanhamento multiprofissional rigoroso, diante dos potenciais riscos de interação medicamentosa e implicações clínicas.

Referências

1. Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, et al. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Med. 2021;18:e1003731. DOI: https://doi.org/10.1371/journal.pmed.1003731

2. Deng Y, Huang H, Shi J, Jin H. Identification of Candidate Genes in Breast Cancer Induced by Estrogen Plus Progestogens Using Bioinformatic Analysis. Int J Mol Sci. 2022 Oct 6;23(19):11892. doi: 10.3390/ijms231911892. PMID: 36233194; PMCID: PMC9569986. DOI: https://doi.org/10.3390/ijms231911892

3. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150. DOI: https://doi.org/10.3109/13697137.2015.1129166

4. North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2018;25:1362–1387.

5. Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, et al. The 2020 Menopausal Hormone Therapy Guidelines. J Menopausal Med. 2020;26:69–98. DOI: https://doi.org/10.6118/jmm.20000

6. Pinkerton JV. Hormone Therapy for Postmenopausal Women. N Engl J Med. 2020;382:446–455. DOI: https://doi.org/10.1056/NEJMcp1714787

7. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.

8. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(Suppl 1):s1–s66. DOI: https://doi.org/10.1210/jc.2009-2509

9. Lambrinoudaki I. Menopausal hormone therapy and breast cancer risk: All progestogens are not the same. Case Rep Womens Health. 2021;29:e00270. DOI: https://doi.org/10.1016/j.crwh.2020.e00270

10. Stevenson JC, Farmer RDT. HRT and breast cancer: A million women ride again. Climacteric. 2020;23:226–228. DOI: https://doi.org/10.1080/13697137.2020.1735797

11. Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy—Where are we now? Climacteric. 2021;24:3–10. DOI: https://doi.org/10.1080/13697137.2020.1851183

12. Flores VA, Taylor HS. The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk. Endocrinol Metab Clin North Am. 2015;44:587–602. DOI: https://doi.org/10.1016/j.ecl.2015.05.007

13. Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, et al. Menopausal hormone therapy trends before versus after 2002: Impact of the Women’s Health Initiative Study Results. Menopause. 2018;26:588–597. DOI: https://doi.org/10.1097/GME.0000000000001282

14. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: Long-term effects of the Women’s Health Initiative. Menopause. 2012;19:616–621. DOI: https://doi.org/10.1097/gme.0b013e31824bb039

15. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. DOI: https://doi.org/10.1001/jama.288.3.321

16. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712. DOI: https://doi.org/10.1001/jama.291.14.1701

17. Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020;324:369–380. DOI: https://doi.org/10.1001/jama.2020.9482

18. Armeni E, Cano A, Rees M, Lambrinoudaki I. Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety. Maturitas. 2020;141:85–86. DOI: https://doi.org/10.1016/j.maturitas.2020.08.001

19. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–111. DOI: https://doi.org/10.1007/s10549-007-9523-x

20. Purmonen S, Manninen T, Pennanen P, Ylikomi T. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep. 2008;19:1627–1634.

21. Traboulsi T, El Ezzy M, Gleason JL, Mader

S. Antiestrogens: Structure-activity relationships and use in breast cancer treatment. J Mol Endocrinol. 2017;58:R15–R31. DOI: https://doi.org/10.1530/JME-16-0024

22. Almutairi MS, Al Suwayyid AN, Aldarwesh A, Aboulwafa OM, Attia MI. Antiestrogenic Activity and Possible Mode of Action of Certain New Nonsteroidal Coumarin-4-acetamides. Molecules. 2020;25:1553. DOI: https://doi.org/10.3390/molecules25071553

23. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. J Biol Chem. 1978;253:2223–2228. DOI: https://doi.org/10.1016/S0021-9258(17)38062-6

24. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen. Endocrinology. 1978;103:1742–1751. DOI: https://doi.org/10.1210/endo-103-5-1742

25. Chlebowski RT, Manson JE. Menopausal Hormone Therapy and Breast Cancer. Cancer J. 2022;28:169–175. DOI: https://doi.org/10.1097/PPO.0000000000000601

26. Murkes D, Conner P, Leifland K, Tani E, Beliard A, Lundström E, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril. 2011;95:1188–1191. DOI: https://doi.org/10.1016/j.fertnstert.2010.09.062

27. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171–208. DOI: https://doi.org/10.1210/er.2012-1008

28. Santen RJ, Yue W. Cause or prevention of breast cancer with estrogens: Analysis from tumor biologic data, growth kinetic model and Women’s Health Initiative study. Climacteric. 2019;22:3–12. DOI: https://doi.org/10.1080/13697137.2017.1388364

29. Santen RJ, Yue W, Heitjan DF. Modeling of the growth kinetics of occult breast tumors: Role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev. 2012;21:1038–1048. DOI: https://doi.org/10.1158/1055-9965.EPI-12-0043

30. Suski JM, Braun M, Strmiska V, Sicinski P. Targeting cell-cycle machinery in cancer. Cancer Cell. 2021;39:759–778. DOI: https://doi.org/10.1016/j.ccell.2021.03.010

31. Ward AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, et al. Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism. Cancers. 2022;14:1776. DOI: https://doi.org/10.3390/cancers14071776

32. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: A hypothesis. J Clin Endocrinol Metab. 2008;93:3295–3298. DOI: https://doi.org/10.1210/jc.2008-0938

33. Horwitz KB, Sartorius CA. 90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: Past, present, future. J Mol Endocrinol. 2020;65:T49–T63. DOI: https://doi.org/10.1530/JME-20-0104

34. Need EF, Selth LA, Trotta AP, Leach DA, Giorgio L, O’Loughlin MA, et al. The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer. 2015;15:791. DOI: https://doi.org/10.1186/s12885-015-1819-3

35. Wood CE, Register TC, Cline JM. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat. 2009;114:233–242. DOI: https://doi.org/10.1007/s10549-008-0003-8

36. Atwood CS, Ekstein SF. Human versus non-human sex steroid use in hormone replacement therapies part 1: Preclinical data. Mol Cell Endocrinol. 2019;480:12–35. DOI: https://doi.org/10.1016/j.mce.2018.10.003

37. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277–283. DOI: https://doi.org/10.1016/j.maturitas.2004.01.001

38. Cabeza M, Heuze Y, Sánchez A, Garrido M, Bratoeff E. Recent advances in structure of progestins and their binding to progesterone receptors. J Enzyme Inhib Med Chem. 2015;30:152–159. DOI: https://doi.org/10.3109/14756366.2014.895719

39. King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril. 1986;46:1062–1066. DOI: https://doi.org/10.1016/S0015-0282(16)49880-8

40. North American Menopause Society. NAMS 2017 Guidelines. Menopause. 2018;25:1362–1387. DOI: https://doi.org/10.1097/GME.0000000000001241

41. Endocrine Society. Hormone therapy clinical practice guidelines. J Clin Endocrinol Metab. 2015;100:3975–4011. DOI: https://doi.org/10.1210/jc.2015-2236

42. Lobo RA. Hormone replacement: Risks and benefits after WHI. Climacteric. 2017;20:105–112.

43. Beral V. Million Women Study: Breast cancer and hormone-replacement therapy. Lancet. 2003;362:419–427. DOI: https://doi.org/10.1016/S0140-6736(03)14065-2

44. Davis SR, Lambrinoudaki I, Lumsden MA, Mishra GD, Pal L, Rees M, et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2017;20:304–312.

45. MacLennan AH. HRT and breast cancer: Weighing evidence. Maturitas. 2014;78:114–116.

46. Writing Group for the PEPI Trial. Effects of hormone replacement therapy regimens on risk markers for cardiovascular disease in postmenopausal women. JAMA. 1995;273:199–208. DOI: https://doi.org/10.1001/jama.1995.03520270033028

47. Anderson GL. Overview of WHI findings in hormone therapy. Semin Reprod Med. 2005;23:11–17.

48. Pinkerton JV. Emerging regimens in hormone therapy for menopause.

Menopause. 2021;28:242–249.

49. Gambacciani M. HRT and breast safety in postmenopausal women. Climacteric. 2009;12:111–117. DOI: https://doi.org/10.1080/13697130903013445

50. Shapiro S. Reanalysis of WHI data on HRT and breast cancer. Climacteric. 2018;21:286–292.

51. Fugh-Berman A. Drug interactions in women taking HRT and tamoxifen. Am J Obstet Gynecol. 2002;187:S25–S32.